San Jose, Calif. – September 13, 2026 -- Anixa Biosciences, Inc. (NASDAQ: ANIX) confirmed that Bloomberg TV will air an interview with Chairman and CEO Dr. Amit Kumar and breast cancer vaccine trial patient Sherie Steinberg this Saturday, September 12, at 7:00 PM ET, reaching an estimated 73 million U.S. homes.
Bloomberg TV segment to spotlight breast cancer vaccine data and patient outcomes
The interview will air on the RedChip Small Stocks, Big Money show and is also available online. Dr. Kumar is expected to detail recent progress in Anixa's cancer vaccine development program, including a breast cancer vaccine designed for three applications: treating existing disease, preventing recurrence, and reducing the risk of initial onset in high-risk patients.
Phase 1 trial participant to share direct clinical experience with investors
Sherie Steinberg, a breast cancer survivor who received Anixa's vaccine during its Phase 1 clinical trial, will describe her treatment journey and firsthand experience with the therapy on the broadcast.
Anixa's oncology pipeline spans vaccine and cell therapy programs with academic partners
Anixa's vaccine portfolio, developed with Cleveland Clinic, targets breast and ovarian cancer along with additional high-incidence malignancies in lung, colon, and prostate. Cleveland Clinic holds rights to royalties and other commercialization revenues tied to these licensed technologies. Separately, Anixa is developing an ovarian cancer immunotherapy, liraltagene autoleucel (lira-cel), with Moffitt Cancer Center, using a chimeric endocrine receptor-T cell (CER-T) approach in which the natural FSH ligand binds the FSHR receptor on tumor cells rather than relying on an antibody fragment.